Efficacy and Safety of Datopotamab Deruxtecan in Patients with Pretreated Advanced/Metastatic NSCLC with Actionable Genomic Alterations By Ogkologos - January 27, 2025 326 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TROPION-Lung05 study Source RELATED ARTICLESMORE FROM AUTHOR Solid Organ Transplant Recipients with Pretransplant Cancer Have an Elevated Risk of Posttransplant Cancer of the Same Cancer Type Population-based lung cancer screening can reduce mortality in people who have never smoked, study shows in China EMA Recommends Granting a Conditional Marketing Authorisation for Tovorafenib MOST POPULAR Sentinel Lymph Node Biopsy Navigated Neck Dissection Is Not Inferior to... April 22, 2021 Why ASCO’s Annual Meeting Matters for People With Cancer and How... June 1, 2021 Singer Surprises 6-Year-Old Fan Who Beat Cancer With Trip To Disney January 10, 2022 BRAF Inhibitor and Rituximab for the Management of Refractory or Relapsed... May 19, 2021 Load more HOT NEWS The Unique Challenges Teenagers and Young Adults With Cancer Face: An... Transforming optimism: finding new ways to treat rare cancers Capmatinib Shows Activity in Advanced NSCLC with a MET Exon 14... Marginal Benefit in Overall and Progression-Free Survival from New Anticancer Drugs
